Tag Archives: Pfizer Inc.

Pfizer, Merck’s Bavencio flop illustrative of shattered Pharma model. Is industry’s collapse just around the corner?

The News: Pfizer Inc. (NYC) and its German part­ner Merck KGaA (Darmstadt) have run into a brick wall in their race to ex­pand the mar­ket for their PD-L1 check­point inhibitor Baven­cio… Read more »

MannKind’s 10-year quest for insulin product Afrezza gets last-ditch chance; time to buy, or run?

The News: Last week, MannKind Corp. (Nasdaq:MNKD) led advancing stocks in the healthcare sector, soaring 151% to $5.03, after saying it won a labeling concession from the FDA on its Afrezza inhalable… Read more »

China’s FDA to accept foreign trial data for accelerated approvals; sounds great, but future enforcement of IP rights poses threat to US Pharma.

The News: For decades, patients in China have fought to gain access to cutting-edge medicines thanks to bureaucratic delays that have thwarted drug development. Now a sweeping government overhaul of… Read more »

Humdrum, stodgy Pfizer suddenly turns heads with partial drug-pipeline spinoff; old dog apparently can learn new tricks.

The News: Pfizer Inc. (NYC) on Monday (September 25, 2017) announced that it is spinning off a new company, SpringWorks Therapeutics LLC, to develop several drugs for rare diseases that… Read more »

Pfizer granted Prevnar patent from India; drugmaker draws quick fire for pricing, access.

The News: India has granted Pfizer Inc. (NYC) a patent for its powerful pneumonia vaccine Prevenar 13, in a blow to some health groups that said this would put the… Read more »

Tesaro says it’s for sale, but who can afford it

The News: Just ahead of the year’s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street… Read more »

What’s wrong with Novartis? Actually nothing.

The News: Novartis AG (Basel CHE) has been the subject of widespread and lingering chatter to the effect that its stature among the Big Pharma league players has diminished, and… Read more »

Pfizer’s mixed 1Q results spur M&A hopes; is Bristol-Myers a “done deal”?

The News: Pfizer Inc. said Tuesday (May 2, 2017) that first-quarter sales declined 2% year-over-year to $12.8 billion, missing analyst estimates of $13.1 billion, with the company highlighting one less… Read more »

Wall Street cheers as Axovant snags biotech star David Hung; failed Alzheimer’s drug not impressed

The News: Axovant Sciences Ltd. (Hamilton Bermuda) announced that former Medivation Inc. (San Francisco) chief executive and founder David Hung has been selected as its next CEO effective April 7, 2017 sending… Read more »